Boehringer Ingelheim, a leading contract manufacturer for biopharmaceutical medicines, has rounded off its full-service capabilities for customers with a new filling line at Shanghai, China.
With this latest extension the contract manufacturing business Boehringer Ingelheim BioXcellence™ now offers manufacturing of drug substance, drug product and all corresponding quality control and assurance activities to their customers under one roof at its commercial manufacturing facility OASIS in Shanghai. The new isolator based fill & finish line is in full GMP operations for aseptic filling of liquids in vials.
Fill & finish as the final manufacturing step is critical to ensure the safety and efficacy of a biopharmaceutical medicine. Under aseptic conditions the drug substance is filled into containers before labelling and packaging as final drug product. The new line with isolator technique represents one further step in Boehringer Ingelheim’s one stop shop for contract development and manufacturing of biopharmaceuticals at its site in Shanghai. With this state-of–the-art technology Boehringer Ingelheim BioChina offers further excellence and solutions in the contract manufacturing business to its local and global customers.
Represented by the brand Boehringer Ingelheim BioXcellence™, it offers tailor-made contract development and manufacturing services to the industry, providing the entire production technology chain from DNA to fill and finish through its network in Biberach (Germany), Vienna (Austria), Fremont (USA) and Shanghai (China). Boehringer Ingelheim BioXcellence™ secures supply throughout the entire product lifecycle — transferring customer projects at any stage, delivering to almost any scale and thereby making outsourcing easy.
Headquartered in Ingelheim Germany, Boehringer Ingelheim presently with a total of some 50,000 employees. The company entered into the Chinese market in 1994, headquartered in Shanghai with more than 3500 employees.
Boehringer Ingelheim is one of the world’s largest manufacturers of biopharmaceuticals. With over 35 years of experience in this field, the company is an industry pioneer and has produced more than 25 biopharmaceuticals for global markets.